Efficacy of Transcranial Direct Current Stimulation In Parkinson's Disease MCI (PDMCIStim)
Efficacy of Prefrontal Transcranial Direct Current Stimulation On Cognitive Functions and Electrophysiological Measures In Parkinson's Disease Mild Cognitive Impairment
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Parkinson's Disease (PD) is the second most common neurodegenerative disorder. The period that apparent cognitive deficits exist without disrupting daily life activities is named as Mild Cognitive Impairment (PD-MCI). Treatments were considered to be more efficacious in PD-MCI than PD dementia as relatively less permanent changes in cortical structures occured. No approved treatments exist in PD-MCI and non-pharmacological treatments are under investigation as drugs have considerable amount of adverse effects.
Event Related Potentials (ERP) measurements have the advantages of providing direct and objective evidence of central nervous system functions, imaging of the activity of the cortical areas and being unaffected by motor deficits. ERP parameters were found to be related to cognitive functions and disrupted in PD and PD-MCI. Thus, ERP parameters were suggested to be useful in treatment efficacy assessment.
Transcranial Direct Current Stimulation (tDCS) is a promising non-invasive brain stimulation method. Ameliorating effects of tDCS on cognition and ERPs were observed. Enhancing effects of tDCS on some cognitive deficits were also reported in PD.
Few studies reported the efficacy of both tDCS and physical therapy/cognitive training and none assessed the efficacy of tDCS solely, compared to a sham control group. All studies assessed the efficacy without using electrophysiological measurements that reflect central nervous system functions directly. In this project, the efficacy of tDCS will be compared to a sham tDCS group and be assessed with electrophysiological measurements for the first time.
The study is a double-blind randomized controlled trial. The sample will be consisted of twenty six participants diagnosed as having PD-MCI due to Movement Disorders Society Level 2 criteria. The participants will be assigned to active or sham groups. Then, neuropsychological test performances and ERP parameters during Oddball paradigm and Continuous Performance Test will be measured. Then, participants will be applied ten active or sham sessions of left anodal/right cathodal tDCS over the dorsolateral prefrontal cortex (DLPFC). All measurements will be repeated both immediately and 1-month after the applications.
Succinctly, the aim of this project is to assess the effect of ten sessions left anodal/right cathodal tDCS over the DLPFC on cognitive functions and electrophysiological parameters in PD-MCI.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Istanbul, Pavo
- Istanbul University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Clinical diagnosis of PD with at least two of the four diagnostic criteria for PD (tremor, rigidity, bradykinesia, and postural instability) in accordance with the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria, issued by a neurologist specializing in movement disorders;
- Disease staging between I and III, according to the modified Hoehn and Yahr scale;
- Clinical diagnosis of PD- MCI in accordance with Level 2 Movement Disorders Society- Task Force diagnostic criteria;
- An unchanged stable and optimal regimen of dopaminergic medication for at least one month before study entry and able to continue on a stable regimen for the duration of the study;
- Ability to provide written informed consent;
- 5 or more years of education;
- Right-hand dominancy;
- Not taking any psychoactive medications before the previous month of the study and for the duration of the study;
- Naïve to tDCS.
Exclusion Criteria:
- Diagnosis or evidence of secondary or atypical parkinsonism;
- Patients with dementia;
- Less than 5 years of education;
- Previous history of surgical intervention for PD such as deep brain stimulation (DBS);
- Diagnosis of active major depressive disorder, psychotic disorders, bipolar disorder, alcohol use disorder and substance use disorders;
- Any history of any clinically significant neurological disorder, including organic brain disease, epilepsy, stroke, brain lesions, multiple sclerosis, previous neurosurgery, or personal history of head trauma that resulted in loss of consciousness for > 5 minutes and retrograde amnesia for > 30 minutes;
- Significant hearing loss or visual impairment;
- Diagnosis of any serious or uncontrolled medical condition such as chronic obstructive pulmonary disease, congestive heart failure or renal failure;
- Skin diseases that could potentially cause irritations under electrodes
- Patients missing two consecutive protocol sessions;
- Illiteracy, deficient language or refusal to participate or being not able to follow instructions or complete study tasks;.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Active
Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
|
Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval).
During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Otros nombres:
|
|
Comparador falso: Sham
Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
|
Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval).
During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in response conflict in the Stroop Test during the study period
Periodo de tiempo: Up to one month
|
The stroop effect consists of the semantic and the response conflict.
Response conflict (time in milliseconds) is obtained by subtracting the semantic conflict (time in milliseconds obtained in the second step of the protocol) from the stroop effect (time in milliseconds obtained in the first step of the protocol).
Minimum time difference is 0 and maximum time difference is 100 milliseconds.
Lower time differences indicate better performance and higher time differences indicate worse performance.
|
Up to one month
|
|
Change in the verbal fluency performance during the study period
Periodo de tiempo: Up to one month
|
Verbal fluency is a test that measure multiple domains of cognition such as executive functions and language functions.
Letter Verbal Fluency assesses the number of words beginning with certain letters that participants can generate within 60 seconds, the Category Verbal Fluency assesses the number of words within particular categories participants can generate within 60 seconds.
Minimum score is 0 and maximum score is 80. Lower scores indicate worse performance and higher scores indicate better performance.
|
Up to one month
|
|
Changes in Trail Making A Test performance during the study period
Periodo de tiempo: Up to one month
|
Trail Making A Test is a widely used as a quick and easy to administer measure of attention.
Lower reaction times indicate better performance and higher reaction times indicate worse performance.
Minimum time is 10 milliseconds and maximum time is 150 milliseconds.
|
Up to one month
|
|
Changes in digit span during the study period
Periodo de tiempo: Up to one month
|
The Digit Span test is a measure of verbal short-term/working memory. Subjects must recall all digits either in forward (digit span forward) or backward (digit span backward) order. Digit span forward total score: 0-10; higher score indicate better performance, digit span backwards total score: 0-10; higher score indicate better performance |
Up to one month
|
|
Changes in delayed recall performance during the study period
Periodo de tiempo: Up to one month
|
Memory performance was assessed using delayed recall (number of units recalled) on the Wechsler Memory Scale (WMS-IV) logical memory (story recall) test.
Scores represent a sum of recalled units of two different stories after a 30 minute delay.
Total scores range from 0 to 50 (0-25 for each story) with higher scores reflecting better memory performance.
|
Up to one month
|
|
Changes in verbal memory processes performance during the study period
Periodo de tiempo: Up to one month
|
The Verbal Memory Processes Test is a 15-word word-list learning test with a 40-minute delayed recall addition based on the Rey Auditory Verbal Learning Test which gives the opportunity to evaluate the processes of working memory, learning or acquiring knowledge, retention of information, and recalling. It consists of immediate recall, learning score and a 40-min delayed recall test, followed by total recall. Higher scores indicate better performance in all indexes of the test. Minimum scores are 0 and maximum scores are 15 for immediate recall, delayed recall and total recall and 150 for learning score, respectively. |
Up to one month
|
|
Changes in face recognition performance during the study period
Periodo de tiempo: Up to one month
|
Benton Facial Recognition Test is a common test assessing visuo-spatial functions.
It was developed by Benton in 1969.
It is standardized to determine the capacity to identify and distinguish unrecognized human faces.
This test consists of 22 pages of A4 size and there are face pictures on these pages.
Only one page of pages is numbered.
There is a stimulant picture on pages with no page numbers.
Numbered pages have 6 pictures to select from among the responses.
The application period of the test is 5-15 minutes and the time factor is not evaluated separately.
Higher scores indicate better performance and lower scores indicate worse performance.
Minimum score is 0 and maximum score is 54.
|
Up to one month
|
|
Changes in judgment of line orientation performance during the study period
Periodo de tiempo: Up to one month
|
A test of visuospatial judgement.
The test measured the participant's ability to match the angle and orientation of lines in space.
There were 30 trial in total.
Correct response in a trial was awarded one point.
Minimum score is 0 and maximum score is 30.
Higher scores represent better performances.
|
Up to one month
|
|
Changes in the naming performance during the study period
Periodo de tiempo: Up to one month
|
The naming performance will be measured by the Boston Naming Test Short Form and Responsive Naming Test.
Boston Naming Test consists of 45 pictures to be named.
Minimum score is 0 and maximum score is 45.
Higher scores indicate better performance and lower scores indicate worse performance.
In the Responsive Naming Test, participants answer the questions such as "What do women apply to their lips?"
Minimum score is 0 and maximum score is 10.
Higher scores indicate better performance and lower scores indicate worse performance.
|
Up to one month
|
|
Changes in amplitudes (in microvolts) for parameters from the ERP tests during the study period for parameters from the ERP tests during the study period
Periodo de tiempo: Up to one month
|
Amplitudes (in microvolts) for the following parameters from the ERP tests will be collected as primary endpoints:N1, P3 and other common wave forms for both Two-tone auditory oddball paradigm and Continuous Performance Test ERP paradigms.
|
Up to one month
|
|
Changes in detection sensitivity from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period
Periodo de tiempo: Up to one month
|
Detection sensitivity from Signal Detection Theory (d', calculated as [zFA - zHR], where z is the inverse of the standard normal cumulative distribution, FA is the false-alarm rate [the proportion of responses made to stimuli that were not targets], and HR is the hit rate [the proportion of correct identifications of target stimuli]) during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms will be measured.
|
Up to one month
|
|
Changes in reaction times from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period
Periodo de tiempo: Up to one month
|
Reaction times for the correct behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms will be measured.
|
Up to one month
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between changes in behavioral measures and changes in amplitudes of ERP components
Periodo de tiempo: Up to one month
|
Correlation between changes in detection sensitivity from the behavioral responses and changes in amplitudes of ERP components during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period
|
Up to one month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Serkan Aksu, Istanbul University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2018-055
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Parkinson
-
ProgenaBiomeReclutamientoEnfermedad de Parkinson | Enfermedad de Parkinson con demencia | Síndrome de Parkinson-Demencia | Enfermedad de Parkinson 2 | Enfermedad de Parkinson 3 | Enfermedad de Parkinson 4Estados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoEnfermedad de Parkinson 6, inicio temprano | Enfermedad de Parkinson (autosómica recesiva, aparición temprana) 7, humana | Enfermedad de Parkinson Autosómica Recesiva, Inicio Temprano | Enfermedad de Parkinson, autosómica recesiva de aparición temprana, digénica, Pink1/Dj1Estados Unidos
-
Assiut UniversityAún no reclutandoMri en Parkinson
-
Medical College of WisconsinRetirado
-
Hacettepe UniversityTerminadoEnfermedad de Parkinson idiopáticaPavo
-
Pôle Saint HélierRennes University Hospital; Réseau Parkinson BretagneTerminadoEnfermedad de Parkinson | Síndrome de ParkinsonFrancia
-
UCB PharmaTerminadoEnfermedad de Parkinson idiopáticaAlemania
-
Samuel Vilchez, PhDNational Autonomous University of Nicaragua; Wake Forest University; GID BIO, Inc. y otros colaboradoresTerminadoEnfermedad de Parkinson y parkinsonismo | Enfermedad de Parkinson idiopáticaNicaragua
-
AbbVie (prior sponsor, Abbott)Quintiles, Inc.TerminadoEnfermedad de Parkinson avanzadaEstados Unidos, Nueva Zelanda
-
UCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.TerminadoEnfermedad de Parkinson Idiopática AvanzadaCorea, república de, Estados Unidos, Malasia, Singapur, Taiwán
Ensayos clínicos sobre Transcranial direct current stimulation
-
University of ArkansasReclutamientoAfasiaEstados Unidos
-
Minneapolis Veterans Affairs Medical CenterCenter for Veterans Research and EducationTerminadoObesidad | Impulsividad | Comer en exceso compulsivamenteEstados Unidos
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)TerminadoAnhedonia | Trastorno depresivo mayorEstados Unidos